968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Martina Goetsch(Pfizer (United States)), Douglas C. Wolf(Piedmont Community College), Andrés Yarur(Cedars-Sinai Medical Center), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Christopher J. Rabbat(Abivax (France)), Geert D’Haens(Amsterdam University Medical Centers), Kevin Shan(Abivax (France)), Michael Chiorean(Swedish Medical Center), Filip J. Baert, Timothy E. Ritter(Unknown), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Sheldon Sloan(Pfizer (United States)), Séverine Vermeire(KU Leuven)
Cited by 8
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k